News

Ellipses Pharma features in the Guardian Innovations In Oncology supplement By leveraging a cloud-based platform, our SAG members provide invaluable scientific and clinical insights, validate asset selection, and offer unbiased input during the drug development process using real-world evidence. This collaborative effort ensures better decision-making, faster development, and increased chances of success in bringing potential [...]

Ellipses Pharma announces intent to accelerate clinical programme following ‘encouraging’ data on next generation selective RET inhibitor Chicago June 5, 2023: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor [...]

Ellipses updates clinicians at Asco on clinical trial programmes Ellipses Pharma (“Ellipses”), a global company drug development company focused on accelerating innovative cancer medicines and treatments, today announces its leadership team will attend the forthcoming American Society of Oncology (ASCO) conference in Chicago where they will brief clinicians on the progress of clinical and pre-clinical [...]

Ellipses Pharma featured in Nature Research Ellipses Pharma: maximizing KOL input to increase the success rate of oncology R&D. Read the full article here. 

EP0042 receives Orphan Drug Designation from the US Food and Drug Administration EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that [...]

Expansion of Scientific Affairs Group More than 200 oncologists worldwide now involved in assessment and selection of potential treatments Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG). Ellipses [...]

Ellipses Pharma features in SCRIP Ellipses Pharma has been featured in SCRIP. Read the full article here.

Ellipses Pharma announces FDA approval of IND application for EP0042 for patients with acute myeloid leukaemia IND approval allows for US trial sites and recruitment of eligible US patients to be added to EP0042’s ongoing phase 1/2 trial Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and [...]

Striving to improve treatment options for Acute Myeloid Leukaemia By Professor Tobias Arkenau, Global Head of Drug Development and Chief Medical Officer, Ellipses Pharma If there is one thing a cancer patient wants beyond fast, effective treatment – it is hope. Initial diagnosis is naturally frightening for patients but the realisation that their prescribed treatment [...]

Ellipses announces first patient dosed with EP0031, a next generation selective RET inhibitor Phase 1/2 trial opened in the US with first patient treated in November 2022 London, UK, 14th December 2022: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces the first dosing of [...]